4D Molecular Therapeutics Q2 net loss widens to $54.7 mln
Overview
4D Molecular Therapeutics Q2 net loss widens to $54.7 mln from $35.0 mln
R&D expenses rise due to Phase 3 trial initiation for 4D-150 in wet AMD
Co streamlines organization, reducing workforce by 25% to extend cash runway
Outlook
4DMT expects 4FRONT-1 data in H1 2027, accelerated from H2 2027
Company initiated 4FRONT-2 trial ahead of schedule
4DMT expects cash to fund operations into 2028
Company aligns with FDA and EMA for Phase 3 trial approval
Result Drivers
ACCELERATED TRIALS - Rapid enrollment in 4FRONT-1 trial for 4D-150 in wet AMD allows for accelerated data readout to H1 2027
STREAMLINED OPERATIONS - Workforce reduction by 25% to focus on late-stage execution and extend cash runway into 2028
POSITIVE TRIAL RESULTS - 60-week data from SPECTRA trial in DME shows favorable tolerability and sustained treatment benefits
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $15,000 | ||
Q2 Net Income | -$54.66 mln | ||
Q2 Basic EPS | -$0.98 | ||
Q2 Operating Expenses | $59.47 mln | ||
Q2 Operating Income | -$59.46 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $30.00, about 81.2% above its August 8 closing price of $5.63
Press Release:
